$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016928 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$720.0K	$485.0K	$126.0K
YoY Change	108.09%	284.92%	-58.0%
Cost Of Revenue	$3.483M	$3.559M	$2.754M
YoY Change	38.1%	29.23%	14.27%
Gross Profit	-$2.763M	-$3.074M	-$2.628M
YoY Change	26.98%	16.97%	24.55%
Gross Profit Margin	-383.75%	-633.81%	-2085.71%
Selling, General & Admin	$10.92M	$13.28M	$10.93M
YoY Change	-27.63%	21.54%	61.93%
% of Gross Profit
Research & Development	$3.292M	$3.151M	$2.362M
YoY Change	-41.66%	33.4%	-65.47%
% of Gross Profit
Depreciation & Amortization	$510.0K	$508.0K	$473.0K
YoY Change	-5.9%	7.4%	5.11%
% of Gross Profit
Operating Expenses	$37.69M	$19.99M	$13.29M
YoY Change	62.12%	50.42%	-2.19%
Operating Profit	-$36.97M	-$19.51M	-$15.92M
YoY Change	61.43%	22.54%	1.4%
Interest Expense	$1.708M	$1.429M	-$5.334M
YoY Change	89.57%	-126.79%	173.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$44.63M	-$27.75M	-$21.25M
YoY Change	-2.34%	30.57%	20.42%
Income Tax
% Of Pretax Income
Net Earnings	-$44.63M	-$27.75M	-$21.25M
YoY Change	-2.34%	30.57%	20.44%
Net Earnings / Revenue	-6198.33%	-5721.86%	-16868.25%
Basic Earnings Per Share	-$5.18	-$3.22	-$2.47
Diluted Earnings Per Share	-$5.18	-$3.22	-$82.30K
COMMON SHARES
Basic Shares Outstanding	8.609M shares	258.3M shares	8.609M shares
Diluted Shares Outstanding	8.609M shares	8.609M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.84M	$40.39M	$101.3M
YoY Change	-74.71%	-60.14%	-24.15%
Cash & Equivalents	$20.84M	$40.39M	$101.3M
Short-Term Investments
Other Short-Term Assets	$2.444M	$1.976M	$4.082M
YoY Change	-45.3%	-51.59%	13.39%
Inventory	$6.861M	$6.768M	$4.057M
Prepaid Expenses	$1.667M	$2.419M
Receivables	$79.00K	$281.0K	$102.0K
Other Receivables	$1.578M	$1.203M	$2.769M
Total Short-Term Assets	$31.89M	$51.84M	$112.3M
YoY Change	-65.62%	-53.86%	-22.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.10M	$11.69M	$14.69M
YoY Change	-8.27%	-20.43%	27.76%
Goodwill	$2.175M	$2.132M
YoY Change	-2.77%
Intangibles	$40.34M	$58.50M
YoY Change	-34.28%
Long-Term Investments
YoY Change
Other Assets	$1.110M	$1.311M	$1.446M
YoY Change	-20.49%	-9.34%	80.75%
Total Long-Term Assets	$56.43M	$76.63M	$81.66M
YoY Change	-28.94%	-6.16%	5.64%
TOTAL ASSETS
Total Short-Term Assets	$31.89M	$51.84M	$112.3M
Total Long-Term Assets	$56.43M	$76.63M	$81.66M
Total Assets	$88.32M	$128.5M	$194.0M
YoY Change	-48.7%	-33.79%	-12.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.353M	$9.837M	$3.927M
YoY Change	30.91%	150.5%	131.0%
Accrued Expenses	$10.91M	$12.18M	$14.67M
YoY Change	-27.62%	-16.98%	29.85%
Deferred Revenue	$845.0K	$649.0K
YoY Change	-2.2%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.990M		$4.744M
YoY Change	-77.33%
Total Short-Term Liabilities	$27.67M	$29.57M	$33.99M
YoY Change	-31.72%	-13.0%	42.82%
LONG-TERM LIABILITIES
Long-Term Debt	$47.84M	$49.36M	$24.79M
YoY Change	126.05%	99.12%	55.9%
Other Long-Term Liabilities	$4.071M	$4.507M	$5.663M
YoY Change	-17.05%	-20.41%	82.68%
Total Long-Term Liabilities	$51.91M	$53.87M	$30.45M
YoY Change	99.11%	76.89%	60.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.67M	$29.57M	$33.99M
Total Long-Term Liabilities	$51.91M	$53.87M	$30.45M
Total Liabilities	$79.58M	$83.44M	$64.44M
YoY Change	19.49%	29.48%	50.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$562.0M	-$517.4M
YoY Change	26.79%
Common Stock	$536.0M	$534.3M
YoY Change	21.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.738M	$45.02M	$129.6M
YoY Change
Total Liabilities & Shareholders Equity	$88.32M	$128.5M	$194.0M
YoY Change	-48.7%	-33.79%	-12.96%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$44.63M	-$27.75M	-$21.25M
YoY Change	-2.34%	30.57%	20.44%
Depreciation, Depletion And Amortization	$510.0K	$508.0K	$473.0K
YoY Change	-5.9%	7.4%	5.11%
Cash From Operating Activities	-$19.21M	-$21.66M	-$19.93M
YoY Change	10.09%	8.69%	200.08%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$534.0K	-$515.0K
YoY Change	-104.64%	-203.69%	-8.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$50.00K	-$534.0K	-$515.0K
YoY Change	-95.36%	3.69%	-8.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		12.00K
YoY Change			-99.94%
NET CHANGE
Cash From Operating Activities	-19.21M	-$21.66M	-19.93M
Cash From Investing Activities	-50.00K	-$534.0K	-515.0K
Cash From Financing Activities	0.000		12.00K
Net Change In Cash	-19.26M	-$22.24M	-20.43M
YoY Change	3.96%	8.86%	-241.66%
FREE CASH FLOW
Cash From Operating Activities	-$19.21M	-$21.66M	-$19.93M
Capital Expenditures	$50.00K	$534.0K	-$515.0K
Free Cash Flow	-$19.26M	-$22.19M	-$19.41M
YoY Change	17.63%	14.32%	219.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000764195
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption		usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37769
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	830-3031
CY2023Q1	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	VBIV
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8608539	shares
CY2023Q1	us-gaap	Cash Cash	40392000	usd
CY2022Q4	us-gaap	Cash Cash	62629000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	281000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6768000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2419000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2309000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1976000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	51836000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	77690000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1311000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1355000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11690000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2992000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3316000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58500000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58345000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2132000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	76625000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	77396000	usd
CY2023Q1	us-gaap	Assets Assets	128461000	usd
CY2022Q4	us-gaap	Assets Assets	155086000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9837000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12973000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18101000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	649000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	409000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	986000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	972000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	29573000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36942000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1961000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2204000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49359000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2365000	usd
CY2023Q1	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	520000	usd
CY2022Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	524000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53866000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53981000	usd
CY2023Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8608539	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8608539	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8608539	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8608539	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	442322000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	442312000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	92021000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90020000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28039000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21440000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517360000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-489609000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45022000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128461000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155086000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3559000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2754000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3151000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2362000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13284000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10930000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	19994000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	16046000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19509000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15920000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1429000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	940000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-6813000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4394000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27751000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21254000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21254000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6599000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5103000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21152000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16151000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.22
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.47
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608539	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608532	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2011000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6599000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45022000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	681000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2502000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21254000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5103000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21254000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	508000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	473000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2011000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2502000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	470000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	410000	usd
CY2023Q1	VBIV	Inventory Reserve InventoryReserve	263000	usd
CY2022Q1	VBIV	Inventory Reserve InventoryReserve	220000	usd
CY2023Q1	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-333000	usd
CY2022Q1	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-342000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-6895000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-4297000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	185000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	94000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	599000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1744000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	118000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-209000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4089000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	928000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-28000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	197000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3204000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-459000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4073000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3350000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-334000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-341000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21656000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19925000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	534000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	515000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-534000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-515000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-47000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	71000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22237000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20357000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40392000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	101337000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1437000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	604000	usd
CY2022Q1	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption	681000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	120000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	146000	usd
CY2023Q1	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2022Q1	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zOf494icgI21" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_829_zawhxQCTO6fi">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on <span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331_zCMho3QTHoa8" title="Entity incorporation, date of incorporation">April 9, 1965</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company and the wholly owned subsidiary of VBI US (“VBI Cda”); SciVac Ltd. an Israeli company (“SciVac”); SciVac Hong Kong Limited (“SciVac HK”); and VBI Vaccines B.V a Netherlands company (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse Stock Split</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company effected a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20230411__20230412__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhvBQFr7hVQd" title="Reverse stock split">1-for-30 reverse stock split</span> (the “Reverse Stock Split”) of its issued and outstanding common shares effective as of April 12, 2023, pursuant to which every 30 of the Company’s issued and outstanding common shares were automatically converted into one common share without any change in the par value per share. <span style="background-color: white">All share and per share amounts, including common shares underlying stock options, restricted stock units, and warrants, and applicable exercise prices, have been retroactively adjusted for all periods presented herein to give effect to the Reverse </span>Stock <span style="background-color: white">Split as required in accordance with United States of America generally accepted accounting principles (“U.S. GAAP”). Per the requirements of the <i>Business Corporations Act</i> (British Columbia), under which the Company is regulated, if fractional shares held by registered shareholders were to be converted into whole shares, each fractional share <span style="background-color: white">remaining after the completion of the </span> Reverse </span>Stock <span style="background-color: white">Split that was less than half of a share was cancelled and each fractional share that was at least half of a share was rounded up to one whole share. No shareholders received cash in lieu of fractional shares.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (“VBI”) is a commercial stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent Organizational Changes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As announced on April 4, 2023, VBI plans to focus the Company’s efforts on the fight against hepatitis B, concentrating on broadening access to PreHevbrio and PreHevbri, where it is available, and advancing its HBV immunotherapeutic candidate, VBI-2601, which has the potential to be part of functional cure regimen for chronic HBV patients. As part of this commitment, we also announced our plans to reduce our workforce by <span id="xdx_909_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230403__20230404__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zjQBIKhmQpih" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_901_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230403__20230404__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zPtkO3G2UHW6" title="Operating expenses and workforce reduction percentage">35</span>%, a reduction which initiated in April and is expected to be largely completed by the end of June 2023. As a result of this, and other reductions in spend, we also expect our operating expenses from normal business to be <span id="xdx_909_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230101__20230630__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zTy7Xicwpnj7" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_902_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230101__20230630__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zZcacRSFYan9" title="Operating expenses and workforce reduction percentage">35</span>% lower in the second half of 2023 as compared to the second half of 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><i>COVID-19 Pandemic</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic has materially negatively affected the global economy, and the ongoing effects of the COVID-19 pandemic, including but not limited to, supply chain issues, global shortages of supplies, materials and products, volatile market conditions and rising global inflation, continue to do so. As a result of the COVID-19 pandemic, our business and results of operations were adversely affected and, as the ongoing effects of the COVID-19 pandemic continue to impact the global economy, these effects may continue to adversely affect our business and results of operations. The extent to which these effects will continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted. Recently, the World Health Organization determined that COVID-19 no longer fit the definition of a public health emergency and the U.S. government announced its plan to let the declaration of a public health emergency associated with COVID-19 expire on May 11, 2023. COVID-19 is expected to remain a serious endemic threat for an indefinite future period and may continue to adversely affect the global economy, and we are unable to predict the full extent of potential delays or impacts on our business, our clinical studies, our research programs, the recoverability of our assets, and our manufacturing. The effects of the COVID-19 pandemic may continue to disrupt or delay our business operations, including with respect to efforts relating to potential business development transactions, and it could continue to disrupt the marketplace which could have an adverse effect on our operations. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20230331_zxU7Ackp88p8" title="Accumulated deficit">517,360</span> and cash of $<span id="xdx_900_eus-gaap--Cash_iI_pn3n3_c20230331_zdadxVrIJdA2" title="Cash">40,392</span> as of March 31, 2023. Cash outflows from operating activities were $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230331_zuu8AVyPu1bj" title="Cash outflows from operating activities">21,656</span> for the three months ended March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, achieve and maintain regulatory approvals, and commercially launch and sell our approved products. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable, other current assets, accounts payable, and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1965-04-09
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-517360000	usd
CY2023Q1	us-gaap	Cash Cash	40392000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21656000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	894000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2520000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1869000	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3354000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3837000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6768000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	1203000	usd
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	4033000	usd
CY2023Q1	VBIV	Other Current Assets OtherCurrentAssets	773000	usd
CY2022Q4	VBIV	Other Current Assets OtherCurrentAssets	2026000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1976000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-669000	usd
CY2023Q1	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
CY2023Q1	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	-2700000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62169000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-669000	usd
CY2022	VBIV	Finite Lived Intangible Assets Cumulative Impairment Charge FiniteLivedIntangibleAssetsCumulativeImpairmentCharge	-300000	usd
CY2022	VBIV	Finite Lived Intangible Assets Cumulative Currency Translation FiniteLivedIntangibleAssetsCumulativeCurrencyTranslation	-2855000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58345000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	155000	usd
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2023Q1	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-290000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2132000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2022Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-295000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	5000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	48888000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49359000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	55699000	usd
CY2023Q1	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5450000	usd
CY2022Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6561000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3215000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3250000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2531000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4036000	usd
CY2023Q1	VBIV	Deferred Funding Current DeferredFundingCurrent	6154000	usd
CY2022Q4	VBIV	Deferred Funding Current DeferredFundingCurrent	6966000	usd
CY2023Q1	VBIV	Other Current Liabilities OtherCurrentLiabilities	751000	usd
CY2022Q4	VBIV	Other Current Liabilities OtherCurrentLiabilities	1775000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18101000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1128106	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	871322	shares
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	49359000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1461000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	607000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	470000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	410000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	502000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	77000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1429000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	940000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9446	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9317	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0356	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0171	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M3D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.25
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.50
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2011000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2502000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2610000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2803000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7000	usd
CY2023Q1	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	-4000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2610000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	649000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1961000	usd
CY2018Q4	VBIV	Additional Potential Regulatory And Sales Milestone Payments AdditionalPotentialRegulatoryAndSalesMilestonePayments	117500000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2610000	usd
CY2023Q1	VBIV	Deferred Funding Current DeferredFundingCurrent	6154000	usd
CY2020Q3	VBIV	Contribution Agreement Description ContributionAgreementDescription	75% of VBI Cda’s costs incurred in respect of the Project, subject to certain eligibility limitations as set forth in the Contribution Agreement and (ii) CAD $56 million from the SIF to support the development of our coronavirus vaccine program, VBI-2900, though Phase II clinical studies (the “Project”)
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	491000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	341000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M26D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M20D
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	970000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1193000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	686000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	594000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	163000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3606000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	594000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3012000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	986000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	485000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	126000	usd

Files In Submission

Name	View Source	Status
0001493152-23-016928-index-headers.html	Edgar Link	pending
0001493152-23-016928-index.html	Edgar Link	pending
0001493152-23-016928.txt	Edgar Link	pending
0001493152-23-016928-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-4_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20230331.xsd	Edgar Link	pending
vbiv-20230331_def.xml	Edgar Link	unprocessable
vbiv-20230331_cal.xml	Edgar Link	unprocessable
vbiv-20230331_lab.xml	Edgar Link	unprocessable
vbiv-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2023 Q2 Form 10-Q Financial Statement

#000149315223016928 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2023 Q2 Form 10-Q Financial Statement

#000149315223016928 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq